Pharma & Healthcare
Global Varicella Attenuated Live Vaccine Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
- May 05, 25
- ID: 220114
- Pages: 80
- Figures: 80
- Views: 49
The global Varicella Attenuated Live Vaccine market size was US$ 2776 million in 2024 and is forecast to a readjusted size of US$ 3712 million by 2031 with a CAGR of 4.3% during the forecast period 2025-2031.
A live attenuated varicella vaccine, derived from the Oka strain of VZV has clinical efficacy for the prevention of varicella.
For the major players of Varicella Attenuated Live Vaccine, Merck maintained its first place in the ranking in 2019, followed by BCHT, Shanghai Institute, GSK and Keygen. Top 5 players accounted for about 95% of the Global Varicella Attenuated Live Vaccine revenue market share in 2019.
The sales market for Varicella Attenuated Live Vaccine was divided into five geographic regions. Asia-Pacific occupied the largest sales market share with about 58% in 2019. It is followed by North America and Europe with about 18% and about 13% respectively, while other regions have smaller market.
The global Varicella Attenuated Live Vaccine market is strategically segmented by company, region (country), by Type, and by Application. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on sales, revenue, and forecasts across regions, by Type, and by Application for 2020-2031.
Market Segmentation
By Company:
Merck
BCHT
Shanghai Institute
GSK
Keygen
Green Cross
Biken
Shanghai Rongsheng Biotech
Changchun Changsheng Life Sciences Limited
By Type: (Dominant Segment vs High-Margin Innovation)
Monovalent Vaccine
Combination Vaccine
By Application: (Core Demand Driver vs Emerging Opportunity)
Kids Injection
Adults Injection
By Region
Macro-Regional Analysis: Market Size & Growth Forecasts
- North America
- Europe
- Asia-Pacific
- South America
- Middle East & Africa
Micro-Local Market Deep Dive: Strategic Insights
- Competitive Landscape: Player dominance vs. disruptors (e.g., Merck in Europe)
- Emerging Product Trends: Monovalent Vaccine adoption vs. Combination Vaccine premiumization
- Demand-Side Dynamics: Kids Injection growth in China vs. Adults Injection potential in North America
- Localized Consumer Needs: Regulatory hurdles in EU vs. price sensitivity in India
Focus Markets:
North America
Europe
China
Japan
South Korea
Chapter Outline
Chapter 1: Report scope, executive summary, and market evolution scenarios (short/mid/long term).
Chapter 2: Quantitative analysis of Varicella Attenuated Live Vaccine market size and growth potential at global, regional, and country levels.
Chapter 3: Competitive benchmarking of manufacturers (revenue, market share, M&A, R&D focus).
Chapter 4: Type-based segmentation analysis – Uncovering blue ocean markets (e.g., Combination Vaccine in China).
Chapter 5: Application-based segmentation analysis – High-growth downstream opportunities (e.g., Adults Injection in India).
Chapter 6: Regional sales and revenue breakdown by company, type, application and customer.
Chapter 7: Key manufacturer profiles – Financials, product portfolios, and strategic developments.
Chapter 8: Market dynamics – Drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 9: Actionable conclusions and strategic recommendations.
Why This Report?
This is not just another market study. By fusing global trend analysis with hyper-local operational intelligence, we deliver:
- Risk-Controlled Market Entry: Navigate regulatory complexities in focus markets (e.g., China’s policies).
- Product Portfolio Optimization: Align offerings with regional preferences (e.g., Monovalent Vaccine dominance in Europe vs. Combination Vaccine demand in MEA).
- Competitor Counterstrategies: Decode player tactics in fragmented vs. consolidated markets.
A live attenuated varicella vaccine, derived from the Oka strain of VZV has clinical efficacy for the prevention of varicella.
For the major players of Varicella Attenuated Live Vaccine, Merck maintained its first place in the ranking in 2019, followed by BCHT, Shanghai Institute, GSK and Keygen. Top 5 players accounted for about 95% of the Global Varicella Attenuated Live Vaccine revenue market share in 2019.
The sales market for Varicella Attenuated Live Vaccine was divided into five geographic regions. Asia-Pacific occupied the largest sales market share with about 58% in 2019. It is followed by North America and Europe with about 18% and about 13% respectively, while other regions have smaller market.
The global Varicella Attenuated Live Vaccine market is strategically segmented by company, region (country), by Type, and by Application. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on sales, revenue, and forecasts across regions, by Type, and by Application for 2020-2031.
Market Segmentation
By Company:
Merck
BCHT
Shanghai Institute
GSK
Keygen
Green Cross
Biken
Shanghai Rongsheng Biotech
Changchun Changsheng Life Sciences Limited
By Type: (Dominant Segment vs High-Margin Innovation)
Monovalent Vaccine
Combination Vaccine
By Application: (Core Demand Driver vs Emerging Opportunity)
Kids Injection
Adults Injection
By Region
Macro-Regional Analysis: Market Size & Growth Forecasts
- North America
- Europe
- Asia-Pacific
- South America
- Middle East & Africa
Micro-Local Market Deep Dive: Strategic Insights
- Competitive Landscape: Player dominance vs. disruptors (e.g., Merck in Europe)
- Emerging Product Trends: Monovalent Vaccine adoption vs. Combination Vaccine premiumization
- Demand-Side Dynamics: Kids Injection growth in China vs. Adults Injection potential in North America
- Localized Consumer Needs: Regulatory hurdles in EU vs. price sensitivity in India
Focus Markets:
North America
Europe
China
Japan
South Korea
Chapter Outline
Chapter 1: Report scope, executive summary, and market evolution scenarios (short/mid/long term).
Chapter 2: Quantitative analysis of Varicella Attenuated Live Vaccine market size and growth potential at global, regional, and country levels.
Chapter 3: Competitive benchmarking of manufacturers (revenue, market share, M&A, R&D focus).
Chapter 4: Type-based segmentation analysis – Uncovering blue ocean markets (e.g., Combination Vaccine in China).
Chapter 5: Application-based segmentation analysis – High-growth downstream opportunities (e.g., Adults Injection in India).
Chapter 6: Regional sales and revenue breakdown by company, type, application and customer.
Chapter 7: Key manufacturer profiles – Financials, product portfolios, and strategic developments.
Chapter 8: Market dynamics – Drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 9: Actionable conclusions and strategic recommendations.
Why This Report?
This is not just another market study. By fusing global trend analysis with hyper-local operational intelligence, we deliver:
- Risk-Controlled Market Entry: Navigate regulatory complexities in focus markets (e.g., China’s policies).
- Product Portfolio Optimization: Align offerings with regional preferences (e.g., Monovalent Vaccine dominance in Europe vs. Combination Vaccine demand in MEA).
- Competitor Counterstrategies: Decode player tactics in fragmented vs. consolidated markets.
1 Market Overview
1.1 Varicella Attenuated Live Vaccine Product Scope
1.2 Varicella Attenuated Live Vaccine by Type
1.2.1 Global Varicella Attenuated Live Vaccine Sales by Type (2020 & 2024 & 2031)
1.2.2 Monovalent Vaccine
1.2.3 Combination Vaccine
1.3 Varicella Attenuated Live Vaccine by Application
1.3.1 Global Varicella Attenuated Live Vaccine Sales Comparison by Application (2020 & 2024 & 2031)
1.3.2 Kids Injection
1.3.3 Adults Injection
1.4 Global Varicella Attenuated Live Vaccine Market Estimates and Forecasts (2020-2031)
1.4.1 Global Varicella Attenuated Live Vaccine Market Size in Value Growth Rate (2020-2031)
1.4.2 Global Varicella Attenuated Live Vaccine Market Size in Volume Growth Rate (2020-2031)
1.4.3 Global Varicella Attenuated Live Vaccine Price Trends (2020-2031)
1.5 Assumptions and Limitations
2 Market Size and Prospective by Region
2.1 Global Varicella Attenuated Live Vaccine Market Size by Region: 2020 VS 2024 VS 2031
2.2 Global Varicella Attenuated Live Vaccine Retrospective Market Scenario by Region (2020-2025)
2.2.1 Global Varicella Attenuated Live Vaccine Sales Market Share by Region (2020-2025)
2.2.2 Global Varicella Attenuated Live Vaccine Revenue Market Share by Region (2020-2025)
2.3 Global Varicella Attenuated Live Vaccine Market Estimates and Forecasts by Region (2026-2031)
2.3.1 Global Varicella Attenuated Live Vaccine Sales Estimates and Forecasts by Region (2026-2031)
2.3.2 Global Varicella Attenuated Live Vaccine Revenue Forecast by Region (2026-2031)
2.4 Major Region and Emerging Market Analysis
2.4.1 North America Varicella Attenuated Live Vaccine Market Size and Prospective (2020-2031)
2.4.2 Europe Varicella Attenuated Live Vaccine Market Size and Prospective (2020-2031)
2.4.3 China Varicella Attenuated Live Vaccine Market Size and Prospective (2020-2031)
2.4.4 Japan Varicella Attenuated Live Vaccine Market Size and Prospective (2020-2031)
2.4.5 South Korea Varicella Attenuated Live Vaccine Market Size and Prospective (2020-2031)
3 Global Market Size by Type
3.1 Global Varicella Attenuated Live Vaccine Historic Market Review by Type (2020-2025)
3.1.1 Global Varicella Attenuated Live Vaccine Sales by Type (2020-2025)
3.1.2 Global Varicella Attenuated Live Vaccine Revenue by Type (2020-2025)
3.1.3 Global Varicella Attenuated Live Vaccine Price by Type (2020-2025)
3.2 Global Varicella Attenuated Live Vaccine Market Estimates and Forecasts by Type (2026-2031)
3.2.1 Global Varicella Attenuated Live Vaccine Sales Forecast by Type (2026-2031)
3.2.2 Global Varicella Attenuated Live Vaccine Revenue Forecast by Type (2026-2031)
3.2.3 Global Varicella Attenuated Live Vaccine Price Forecast by Type (2026-2031)
3.3 Different Types Varicella Attenuated Live Vaccine Representative Players
4 Global Market Size by Application
4.1 Global Varicella Attenuated Live Vaccine Historic Market Review by Application (2020-2025)
4.1.1 Global Varicella Attenuated Live Vaccine Sales by Application (2020-2025)
4.1.2 Global Varicella Attenuated Live Vaccine Revenue by Application (2020-2025)
4.1.3 Global Varicella Attenuated Live Vaccine Price by Application (2020-2025)
4.2 Global Varicella Attenuated Live Vaccine Market Estimates and Forecasts by Application (2026-2031)
4.2.1 Global Varicella Attenuated Live Vaccine Sales Forecast by Application (2026-2031)
4.2.2 Global Varicella Attenuated Live Vaccine Revenue Forecast by Application (2026-2031)
4.2.3 Global Varicella Attenuated Live Vaccine Price Forecast by Application (2026-2031)
4.3 New Sources of Growth in Varicella Attenuated Live Vaccine Application
5 Competition Landscape by Players
5.1 Global Varicella Attenuated Live Vaccine Sales by Players (2020-2025)
5.2 Global Top Varicella Attenuated Live Vaccine Players by Revenue (2020-2025)
5.3 Global Varicella Attenuated Live Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Varicella Attenuated Live Vaccine as of 2024)
5.4 Global Varicella Attenuated Live Vaccine Average Price by Company (2020-2025)
5.5 Global Key Manufacturers of Varicella Attenuated Live Vaccine, Manufacturing Sites & Headquarters
5.6 Global Key Manufacturers of Varicella Attenuated Live Vaccine, Product Type & Application
5.7 Global Key Manufacturers of Varicella Attenuated Live Vaccine, Date of Enter into This Industry
5.8 Manufacturers Mergers & Acquisitions, Expansion Plans
6 Region Analysis
6.1 North America Market: Players, Segments, Downstream and Major Customers
6.1.1 North America Varicella Attenuated Live Vaccine Sales by Company
6.1.1.1 North America Varicella Attenuated Live Vaccine Sales by Company (2020-2025)
6.1.1.2 North America Varicella Attenuated Live Vaccine Revenue by Company (2020-2025)
6.1.2 North America Varicella Attenuated Live Vaccine Sales Breakdown by Type (2020-2025)
6.1.3 North America Varicella Attenuated Live Vaccine Sales Breakdown by Application (2020-2025)
6.1.4 North America Varicella Attenuated Live Vaccine Major Customer
6.1.5 North America Market Trend and Opportunities
6.2 Europe Market: Players, Segments, Downstream and Major Customers
6.2.1 Europe Varicella Attenuated Live Vaccine Sales by Company
6.2.1.1 Europe Varicella Attenuated Live Vaccine Sales by Company (2020-2025)
6.2.1.2 Europe Varicella Attenuated Live Vaccine Revenue by Company (2020-2025)
6.2.2 Europe Varicella Attenuated Live Vaccine Sales Breakdown by Type (2020-2025)
6.2.3 Europe Varicella Attenuated Live Vaccine Sales Breakdown by Application (2020-2025)
6.2.4 Europe Varicella Attenuated Live Vaccine Major Customer
6.2.5 Europe Market Trend and Opportunities
6.3 China Market: Players, Segments, Downstream and Major Customers
6.3.1 China Varicella Attenuated Live Vaccine Sales by Company
6.3.1.1 China Varicella Attenuated Live Vaccine Sales by Company (2020-2025)
6.3.1.2 China Varicella Attenuated Live Vaccine Revenue by Company (2020-2025)
6.3.2 China Varicella Attenuated Live Vaccine Sales Breakdown by Type (2020-2025)
6.3.3 China Varicella Attenuated Live Vaccine Sales Breakdown by Application (2020-2025)
6.3.4 China Varicella Attenuated Live Vaccine Major Customer
6.3.5 China Market Trend and Opportunities
6.4 Japan Market: Players, Segments, Downstream and Major Customers
6.4.1 Japan Varicella Attenuated Live Vaccine Sales by Company
6.4.1.1 Japan Varicella Attenuated Live Vaccine Sales by Company (2020-2025)
6.4.1.2 Japan Varicella Attenuated Live Vaccine Revenue by Company (2020-2025)
6.4.2 Japan Varicella Attenuated Live Vaccine Sales Breakdown by Type (2020-2025)
6.4.3 Japan Varicella Attenuated Live Vaccine Sales Breakdown by Application (2020-2025)
6.4.4 Japan Varicella Attenuated Live Vaccine Major Customer
6.4.5 Japan Market Trend and Opportunities
6.5 South Korea Market: Players, Segments, Downstream and Major Customers
6.5.1 South Korea Varicella Attenuated Live Vaccine Sales by Company
6.5.1.1 South Korea Varicella Attenuated Live Vaccine Sales by Company (2020-2025)
6.5.1.2 South Korea Varicella Attenuated Live Vaccine Revenue by Company (2020-2025)
6.5.2 South Korea Varicella Attenuated Live Vaccine Sales Breakdown by Type (2020-2025)
6.5.3 South Korea Varicella Attenuated Live Vaccine Sales Breakdown by Application (2020-2025)
6.5.4 South Korea Varicella Attenuated Live Vaccine Major Customer
6.5.5 South Korea Market Trend and Opportunities
7 Company Profiles and Key Figures
7.1 Merck
7.1.1 Merck Company Information
7.1.2 Merck Business Overview
7.1.3 Merck Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2020-2025)
7.1.4 Merck Varicella Attenuated Live Vaccine Products Offered
7.1.5 Merck Recent Development
7.2 BCHT
7.2.1 BCHT Company Information
7.2.2 BCHT Business Overview
7.2.3 BCHT Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2020-2025)
7.2.4 BCHT Varicella Attenuated Live Vaccine Products Offered
7.2.5 BCHT Recent Development
7.3 Shanghai Institute
7.3.1 Shanghai Institute Company Information
7.3.2 Shanghai Institute Business Overview
7.3.3 Shanghai Institute Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2020-2025)
7.3.4 Shanghai Institute Varicella Attenuated Live Vaccine Products Offered
7.3.5 Shanghai Institute Recent Development
7.4 GSK
7.4.1 GSK Company Information
7.4.2 GSK Business Overview
7.4.3 GSK Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2020-2025)
7.4.4 GSK Varicella Attenuated Live Vaccine Products Offered
7.4.5 GSK Recent Development
7.5 Keygen
7.5.1 Keygen Company Information
7.5.2 Keygen Business Overview
7.5.3 Keygen Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2020-2025)
7.5.4 Keygen Varicella Attenuated Live Vaccine Products Offered
7.5.5 Keygen Recent Development
7.6 Green Cross
7.6.1 Green Cross Company Information
7.6.2 Green Cross Business Overview
7.6.3 Green Cross Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2020-2025)
7.6.4 Green Cross Varicella Attenuated Live Vaccine Products Offered
7.6.5 Green Cross Recent Development
7.7 Biken
7.7.1 Biken Company Information
7.7.2 Biken Business Overview
7.7.3 Biken Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2020-2025)
7.7.4 Biken Varicella Attenuated Live Vaccine Products Offered
7.7.5 Biken Recent Development
7.8 Shanghai Rongsheng Biotech
7.8.1 Shanghai Rongsheng Biotech Company Information
7.8.2 Shanghai Rongsheng Biotech Business Overview
7.8.3 Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2020-2025)
7.8.4 Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccine Products Offered
7.8.5 Shanghai Rongsheng Biotech Recent Development
7.9 Changchun Changsheng Life Sciences Limited
7.9.1 Changchun Changsheng Life Sciences Limited Company Information
7.9.2 Changchun Changsheng Life Sciences Limited Business Overview
7.9.3 Changchun Changsheng Life Sciences Limited Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2020-2025)
7.9.4 Changchun Changsheng Life Sciences Limited Varicella Attenuated Live Vaccine Products Offered
7.9.5 Changchun Changsheng Life Sciences Limited Recent Development
8 Varicella Attenuated Live Vaccine Manufacturing Cost Analysis
8.1 Varicella Attenuated Live Vaccine Key Raw Materials Analysis
8.1.1 Key Raw Materials
8.1.2 Key Suppliers of Raw Materials
8.2 Proportion of Manufacturing Cost Structure
8.3 Manufacturing Process Analysis of Varicella Attenuated Live Vaccine
8.4 Varicella Attenuated Live Vaccine Industrial Chain Analysis
9 Marketing Channel, Distributors and Customers
9.1 Marketing Channel
9.2 Varicella Attenuated Live Vaccine Distributors List
9.3 Varicella Attenuated Live Vaccine Customers
10 Varicella Attenuated Live Vaccine Market Dynamics
10.1 Varicella Attenuated Live Vaccine Industry Trends
10.2 Varicella Attenuated Live Vaccine Market Drivers
10.3 Varicella Attenuated Live Vaccine Market Challenges
10.4 Varicella Attenuated Live Vaccine Market Restraints
11 Research Findings and Conclusion
12 Appendix
12.1 Research Methodology
12.1.1 Methodology/Research Approach
12.1.1.1 Research Programs/Design
12.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
12.1.2 Data Source
12.1.2.1 Secondary Sources
12.1.2.2 Primary Sources
12.2 Author Details
12.3 Disclaimer
1.1 Varicella Attenuated Live Vaccine Product Scope
1.2 Varicella Attenuated Live Vaccine by Type
1.2.1 Global Varicella Attenuated Live Vaccine Sales by Type (2020 & 2024 & 2031)
1.2.2 Monovalent Vaccine
1.2.3 Combination Vaccine
1.3 Varicella Attenuated Live Vaccine by Application
1.3.1 Global Varicella Attenuated Live Vaccine Sales Comparison by Application (2020 & 2024 & 2031)
1.3.2 Kids Injection
1.3.3 Adults Injection
1.4 Global Varicella Attenuated Live Vaccine Market Estimates and Forecasts (2020-2031)
1.4.1 Global Varicella Attenuated Live Vaccine Market Size in Value Growth Rate (2020-2031)
1.4.2 Global Varicella Attenuated Live Vaccine Market Size in Volume Growth Rate (2020-2031)
1.4.3 Global Varicella Attenuated Live Vaccine Price Trends (2020-2031)
1.5 Assumptions and Limitations
2 Market Size and Prospective by Region
2.1 Global Varicella Attenuated Live Vaccine Market Size by Region: 2020 VS 2024 VS 2031
2.2 Global Varicella Attenuated Live Vaccine Retrospective Market Scenario by Region (2020-2025)
2.2.1 Global Varicella Attenuated Live Vaccine Sales Market Share by Region (2020-2025)
2.2.2 Global Varicella Attenuated Live Vaccine Revenue Market Share by Region (2020-2025)
2.3 Global Varicella Attenuated Live Vaccine Market Estimates and Forecasts by Region (2026-2031)
2.3.1 Global Varicella Attenuated Live Vaccine Sales Estimates and Forecasts by Region (2026-2031)
2.3.2 Global Varicella Attenuated Live Vaccine Revenue Forecast by Region (2026-2031)
2.4 Major Region and Emerging Market Analysis
2.4.1 North America Varicella Attenuated Live Vaccine Market Size and Prospective (2020-2031)
2.4.2 Europe Varicella Attenuated Live Vaccine Market Size and Prospective (2020-2031)
2.4.3 China Varicella Attenuated Live Vaccine Market Size and Prospective (2020-2031)
2.4.4 Japan Varicella Attenuated Live Vaccine Market Size and Prospective (2020-2031)
2.4.5 South Korea Varicella Attenuated Live Vaccine Market Size and Prospective (2020-2031)
3 Global Market Size by Type
3.1 Global Varicella Attenuated Live Vaccine Historic Market Review by Type (2020-2025)
3.1.1 Global Varicella Attenuated Live Vaccine Sales by Type (2020-2025)
3.1.2 Global Varicella Attenuated Live Vaccine Revenue by Type (2020-2025)
3.1.3 Global Varicella Attenuated Live Vaccine Price by Type (2020-2025)
3.2 Global Varicella Attenuated Live Vaccine Market Estimates and Forecasts by Type (2026-2031)
3.2.1 Global Varicella Attenuated Live Vaccine Sales Forecast by Type (2026-2031)
3.2.2 Global Varicella Attenuated Live Vaccine Revenue Forecast by Type (2026-2031)
3.2.3 Global Varicella Attenuated Live Vaccine Price Forecast by Type (2026-2031)
3.3 Different Types Varicella Attenuated Live Vaccine Representative Players
4 Global Market Size by Application
4.1 Global Varicella Attenuated Live Vaccine Historic Market Review by Application (2020-2025)
4.1.1 Global Varicella Attenuated Live Vaccine Sales by Application (2020-2025)
4.1.2 Global Varicella Attenuated Live Vaccine Revenue by Application (2020-2025)
4.1.3 Global Varicella Attenuated Live Vaccine Price by Application (2020-2025)
4.2 Global Varicella Attenuated Live Vaccine Market Estimates and Forecasts by Application (2026-2031)
4.2.1 Global Varicella Attenuated Live Vaccine Sales Forecast by Application (2026-2031)
4.2.2 Global Varicella Attenuated Live Vaccine Revenue Forecast by Application (2026-2031)
4.2.3 Global Varicella Attenuated Live Vaccine Price Forecast by Application (2026-2031)
4.3 New Sources of Growth in Varicella Attenuated Live Vaccine Application
5 Competition Landscape by Players
5.1 Global Varicella Attenuated Live Vaccine Sales by Players (2020-2025)
5.2 Global Top Varicella Attenuated Live Vaccine Players by Revenue (2020-2025)
5.3 Global Varicella Attenuated Live Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Varicella Attenuated Live Vaccine as of 2024)
5.4 Global Varicella Attenuated Live Vaccine Average Price by Company (2020-2025)
5.5 Global Key Manufacturers of Varicella Attenuated Live Vaccine, Manufacturing Sites & Headquarters
5.6 Global Key Manufacturers of Varicella Attenuated Live Vaccine, Product Type & Application
5.7 Global Key Manufacturers of Varicella Attenuated Live Vaccine, Date of Enter into This Industry
5.8 Manufacturers Mergers & Acquisitions, Expansion Plans
6 Region Analysis
6.1 North America Market: Players, Segments, Downstream and Major Customers
6.1.1 North America Varicella Attenuated Live Vaccine Sales by Company
6.1.1.1 North America Varicella Attenuated Live Vaccine Sales by Company (2020-2025)
6.1.1.2 North America Varicella Attenuated Live Vaccine Revenue by Company (2020-2025)
6.1.2 North America Varicella Attenuated Live Vaccine Sales Breakdown by Type (2020-2025)
6.1.3 North America Varicella Attenuated Live Vaccine Sales Breakdown by Application (2020-2025)
6.1.4 North America Varicella Attenuated Live Vaccine Major Customer
6.1.5 North America Market Trend and Opportunities
6.2 Europe Market: Players, Segments, Downstream and Major Customers
6.2.1 Europe Varicella Attenuated Live Vaccine Sales by Company
6.2.1.1 Europe Varicella Attenuated Live Vaccine Sales by Company (2020-2025)
6.2.1.2 Europe Varicella Attenuated Live Vaccine Revenue by Company (2020-2025)
6.2.2 Europe Varicella Attenuated Live Vaccine Sales Breakdown by Type (2020-2025)
6.2.3 Europe Varicella Attenuated Live Vaccine Sales Breakdown by Application (2020-2025)
6.2.4 Europe Varicella Attenuated Live Vaccine Major Customer
6.2.5 Europe Market Trend and Opportunities
6.3 China Market: Players, Segments, Downstream and Major Customers
6.3.1 China Varicella Attenuated Live Vaccine Sales by Company
6.3.1.1 China Varicella Attenuated Live Vaccine Sales by Company (2020-2025)
6.3.1.2 China Varicella Attenuated Live Vaccine Revenue by Company (2020-2025)
6.3.2 China Varicella Attenuated Live Vaccine Sales Breakdown by Type (2020-2025)
6.3.3 China Varicella Attenuated Live Vaccine Sales Breakdown by Application (2020-2025)
6.3.4 China Varicella Attenuated Live Vaccine Major Customer
6.3.5 China Market Trend and Opportunities
6.4 Japan Market: Players, Segments, Downstream and Major Customers
6.4.1 Japan Varicella Attenuated Live Vaccine Sales by Company
6.4.1.1 Japan Varicella Attenuated Live Vaccine Sales by Company (2020-2025)
6.4.1.2 Japan Varicella Attenuated Live Vaccine Revenue by Company (2020-2025)
6.4.2 Japan Varicella Attenuated Live Vaccine Sales Breakdown by Type (2020-2025)
6.4.3 Japan Varicella Attenuated Live Vaccine Sales Breakdown by Application (2020-2025)
6.4.4 Japan Varicella Attenuated Live Vaccine Major Customer
6.4.5 Japan Market Trend and Opportunities
6.5 South Korea Market: Players, Segments, Downstream and Major Customers
6.5.1 South Korea Varicella Attenuated Live Vaccine Sales by Company
6.5.1.1 South Korea Varicella Attenuated Live Vaccine Sales by Company (2020-2025)
6.5.1.2 South Korea Varicella Attenuated Live Vaccine Revenue by Company (2020-2025)
6.5.2 South Korea Varicella Attenuated Live Vaccine Sales Breakdown by Type (2020-2025)
6.5.3 South Korea Varicella Attenuated Live Vaccine Sales Breakdown by Application (2020-2025)
6.5.4 South Korea Varicella Attenuated Live Vaccine Major Customer
6.5.5 South Korea Market Trend and Opportunities
7 Company Profiles and Key Figures
7.1 Merck
7.1.1 Merck Company Information
7.1.2 Merck Business Overview
7.1.3 Merck Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2020-2025)
7.1.4 Merck Varicella Attenuated Live Vaccine Products Offered
7.1.5 Merck Recent Development
7.2 BCHT
7.2.1 BCHT Company Information
7.2.2 BCHT Business Overview
7.2.3 BCHT Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2020-2025)
7.2.4 BCHT Varicella Attenuated Live Vaccine Products Offered
7.2.5 BCHT Recent Development
7.3 Shanghai Institute
7.3.1 Shanghai Institute Company Information
7.3.2 Shanghai Institute Business Overview
7.3.3 Shanghai Institute Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2020-2025)
7.3.4 Shanghai Institute Varicella Attenuated Live Vaccine Products Offered
7.3.5 Shanghai Institute Recent Development
7.4 GSK
7.4.1 GSK Company Information
7.4.2 GSK Business Overview
7.4.3 GSK Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2020-2025)
7.4.4 GSK Varicella Attenuated Live Vaccine Products Offered
7.4.5 GSK Recent Development
7.5 Keygen
7.5.1 Keygen Company Information
7.5.2 Keygen Business Overview
7.5.3 Keygen Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2020-2025)
7.5.4 Keygen Varicella Attenuated Live Vaccine Products Offered
7.5.5 Keygen Recent Development
7.6 Green Cross
7.6.1 Green Cross Company Information
7.6.2 Green Cross Business Overview
7.6.3 Green Cross Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2020-2025)
7.6.4 Green Cross Varicella Attenuated Live Vaccine Products Offered
7.6.5 Green Cross Recent Development
7.7 Biken
7.7.1 Biken Company Information
7.7.2 Biken Business Overview
7.7.3 Biken Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2020-2025)
7.7.4 Biken Varicella Attenuated Live Vaccine Products Offered
7.7.5 Biken Recent Development
7.8 Shanghai Rongsheng Biotech
7.8.1 Shanghai Rongsheng Biotech Company Information
7.8.2 Shanghai Rongsheng Biotech Business Overview
7.8.3 Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2020-2025)
7.8.4 Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccine Products Offered
7.8.5 Shanghai Rongsheng Biotech Recent Development
7.9 Changchun Changsheng Life Sciences Limited
7.9.1 Changchun Changsheng Life Sciences Limited Company Information
7.9.2 Changchun Changsheng Life Sciences Limited Business Overview
7.9.3 Changchun Changsheng Life Sciences Limited Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2020-2025)
7.9.4 Changchun Changsheng Life Sciences Limited Varicella Attenuated Live Vaccine Products Offered
7.9.5 Changchun Changsheng Life Sciences Limited Recent Development
8 Varicella Attenuated Live Vaccine Manufacturing Cost Analysis
8.1 Varicella Attenuated Live Vaccine Key Raw Materials Analysis
8.1.1 Key Raw Materials
8.1.2 Key Suppliers of Raw Materials
8.2 Proportion of Manufacturing Cost Structure
8.3 Manufacturing Process Analysis of Varicella Attenuated Live Vaccine
8.4 Varicella Attenuated Live Vaccine Industrial Chain Analysis
9 Marketing Channel, Distributors and Customers
9.1 Marketing Channel
9.2 Varicella Attenuated Live Vaccine Distributors List
9.3 Varicella Attenuated Live Vaccine Customers
10 Varicella Attenuated Live Vaccine Market Dynamics
10.1 Varicella Attenuated Live Vaccine Industry Trends
10.2 Varicella Attenuated Live Vaccine Market Drivers
10.3 Varicella Attenuated Live Vaccine Market Challenges
10.4 Varicella Attenuated Live Vaccine Market Restraints
11 Research Findings and Conclusion
12 Appendix
12.1 Research Methodology
12.1.1 Methodology/Research Approach
12.1.1.1 Research Programs/Design
12.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
12.1.2 Data Source
12.1.2.1 Secondary Sources
12.1.2.2 Primary Sources
12.2 Author Details
12.3 Disclaimer
List of Tables
Table 1. Global Varicella Attenuated Live Vaccine Sales (US$ Million) Growth Rate by Type (2020 & 2024 & 2031)
Table 2. Global Varicella Attenuated Live Vaccine Sales (US$ Million) Comparison by Application (2020 & 2024 & 2031)
Table 3. Global Market Varicella Attenuated Live Vaccine Market Size (US$ Million) by Region:2020 VS 2024 VS 2031
Table 4. Global Varicella Attenuated Live Vaccine Sales (K Doses) by Region (2020-2025)
Table 5. Global Varicella Attenuated Live Vaccine Sales Market Share by Region (2020-2025)
Table 6. Global Varicella Attenuated Live Vaccine Revenue (US$ Million) Market Share by Region (2020-2025)
Table 7. Global Varicella Attenuated Live Vaccine Revenue Share by Region (2020-2025)
Table 8. Global Varicella Attenuated Live Vaccine Sales (K Doses) Forecast by Region (2026-2031)
Table 9. Global Varicella Attenuated Live Vaccine Sales Market Share Forecast by Region (2026-2031)
Table 10. Global Varicella Attenuated Live Vaccine Revenue (US$ Million) Forecast by Region (2026-2031)
Table 11. Global Varicella Attenuated Live Vaccine Revenue Share Forecast by Region (2026-2031)
Table 12. Global Varicella Attenuated Live Vaccine Sales by Type (K Doses) & (2020-2025)
Table 13. Global Varicella Attenuated Live Vaccine Sales Share by Type (2020-2025)
Table 14. Global Varicella Attenuated Live Vaccine Revenue by Type (US$ Million) & (2020-2025)
Table 15. Global Varicella Attenuated Live Vaccine Price by Type (USD/Dose) & (2020-2025)
Table 16. Global Varicella Attenuated Live Vaccine Sales by Type (K Doses) & (2026-2031)
Table 17. Global Varicella Attenuated Live Vaccine Revenue by Type (US$ Million) & (2026-2031)
Table 18. Global Varicella Attenuated Live Vaccine Price by Type (USD/Dose) & (2026-2031)
Table 19. Representative Players of Each Type
Table 20. Global Varicella Attenuated Live Vaccine Sales by Application (K Doses) & (2020-2025)
Table 21. Global Varicella Attenuated Live Vaccine Sales Share by Application (2020-2025)
Table 22. Global Varicella Attenuated Live Vaccine Revenue by Application (US$ Million) & (2020-2025)
Table 23. Global Varicella Attenuated Live Vaccine Price by Application (USD/Dose) & (2020-2025)
Table 24. Global Varicella Attenuated Live Vaccine Sales by Application (K Doses) & (2026-2031)
Table 25. Global Varicella Attenuated Live Vaccine Revenue Market Share by Application (US$ Million) & (2026-2031)
Table 26. Global Varicella Attenuated Live Vaccine Price by Application (USD/Dose) & (2026-2031)
Table 27. New Sources of Growth in Varicella Attenuated Live Vaccine Application
Table 28. Global Varicella Attenuated Live Vaccine Sales by Company (K Doses) & (2020-2025)
Table 29. Global Varicella Attenuated Live Vaccine Sales Share by Company (2020-2025)
Table 30. Global Varicella Attenuated Live Vaccine Revenue by Company (US$ Million) & (2020-2025)
Table 31. Global Varicella Attenuated Live Vaccine Revenue Share by Company (2020-2025)
Table 32. Global Varicella Attenuated Live Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Varicella Attenuated Live Vaccine as of 2024)
Table 33. Global Market Varicella Attenuated Live Vaccine Average Price by Company (USD/Dose) & (2020-2025)
Table 34. Global Key Manufacturers of Varicella Attenuated Live Vaccine, Manufacturing Sites & Headquarters
Table 35. Global Key Manufacturers of Varicella Attenuated Live Vaccine, Product Type & Application
Table 36. Global Key Manufacturers of Varicella Attenuated Live Vaccine, Date of Enter into This Industry
Table 37. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 38. North America Varicella Attenuated Live Vaccine Sales by Company (2020-2025) & (K Doses)
Table 39. North America Varicella Attenuated Live Vaccine Sales Market Share by Company (2020-2025)
Table 40. North America Varicella Attenuated Live Vaccine Revenue by Company (2020-2025) & (US$ Million)
Table 41. North America Varicella Attenuated Live Vaccine Revenue Market Share by Company (2020-2025)
Table 42. North America Varicella Attenuated Live Vaccine Sales by Type (2020-2025) & (K Doses)
Table 43. North America Varicella Attenuated Live Vaccine Sales Market Share by Type (2020-2025)
Table 44. North America Varicella Attenuated Live Vaccine Sales by Application (2020-2025) & (K Doses)
Table 45. North America Varicella Attenuated Live Vaccine Sales Market Share by Application (2020-2025)
Table 46. Europe Varicella Attenuated Live Vaccine Sales by Company (2020-2025) & (K Doses)
Table 47. Europe Varicella Attenuated Live Vaccine Sales Market Share by Company (2020-2025)
Table 48. Europe Varicella Attenuated Live Vaccine Revenue by Company (2020-2025) & (US$ Million)
Table 49. Europe Varicella Attenuated Live Vaccine Revenue Market Share by Company (2020-2025)
Table 50. Europe Varicella Attenuated Live Vaccine Sales by Type (2020-2025) & (K Doses)
Table 51. Europe Varicella Attenuated Live Vaccine Sales Market Share by Type (2020-2025)
Table 52. Europe Varicella Attenuated Live Vaccine Sales by Application (2020-2025) & (K Doses)
Table 53. Europe Varicella Attenuated Live Vaccine Sales Market Share by Application (2020-2025)
Table 54. China Varicella Attenuated Live Vaccine Sales by Company (2020-2025) & (K Doses)
Table 55. China Varicella Attenuated Live Vaccine Sales Market Share by Company (2020-2025)
Table 56. China Varicella Attenuated Live Vaccine Revenue by Company (2020-2025) & (US$ Million)
Table 57. China Varicella Attenuated Live Vaccine Revenue Market Share by Company (2020-2025)
Table 58. China Varicella Attenuated Live Vaccine Sales by Type (2020-2025) & (K Doses)
Table 59. China Varicella Attenuated Live Vaccine Sales Market Share by Type (2020-2025)
Table 60. China Varicella Attenuated Live Vaccine Sales by Application (2020-2025) & (K Doses)
Table 61. China Varicella Attenuated Live Vaccine Sales Market Share by Application (2020-2025)
Table 62. Japan Varicella Attenuated Live Vaccine Sales by Company (2020-2025) & (K Doses)
Table 63. Japan Varicella Attenuated Live Vaccine Sales Market Share by Company (2020-2025)
Table 64. Japan Varicella Attenuated Live Vaccine Revenue by Company (2020-2025) & (US$ Million)
Table 65. Japan Varicella Attenuated Live Vaccine Revenue Market Share by Company (2020-2025)
Table 66. Japan Varicella Attenuated Live Vaccine Sales by Type (2020-2025) & (K Doses)
Table 67. Japan Varicella Attenuated Live Vaccine Sales Market Share by Type (2020-2025)
Table 68. Japan Varicella Attenuated Live Vaccine Sales by Application (2020-2025) & (K Doses)
Table 69. Japan Varicella Attenuated Live Vaccine Sales Market Share by Application (2020-2025)
Table 70. South Korea Varicella Attenuated Live Vaccine Sales by Company (2020-2025) & (K Doses)
Table 71. South Korea Varicella Attenuated Live Vaccine Sales Market Share by Company (2020-2025)
Table 72. South Korea Varicella Attenuated Live Vaccine Revenue by Company (2020-2025) & (US$ Million)
Table 73. South Korea Varicella Attenuated Live Vaccine Revenue Market Share by Company (2020-2025)
Table 74. South Korea Varicella Attenuated Live Vaccine Sales by Type (2020-2025) & (K Doses)
Table 75. South Korea Varicella Attenuated Live Vaccine Sales Market Share by Type (2020-2025)
Table 76. South Korea Varicella Attenuated Live Vaccine Sales by Application (2020-2025) & (K Doses)
Table 77. South Korea Varicella Attenuated Live Vaccine Sales Market Share by Application (2020-2025)
Table 78. Merck Company Information
Table 79. Merck Description and Business Overview
Table 80. Merck Varicella Attenuated Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 81. Merck Varicella Attenuated Live Vaccine Product
Table 82. Merck Recent Development
Table 83. BCHT Company Information
Table 84. BCHT Description and Business Overview
Table 85. BCHT Varicella Attenuated Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 86. BCHT Varicella Attenuated Live Vaccine Product
Table 87. BCHT Recent Development
Table 88. Shanghai Institute Company Information
Table 89. Shanghai Institute Description and Business Overview
Table 90. Shanghai Institute Varicella Attenuated Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 91. Shanghai Institute Varicella Attenuated Live Vaccine Product
Table 92. Shanghai Institute Recent Development
Table 93. GSK Company Information
Table 94. GSK Description and Business Overview
Table 95. GSK Varicella Attenuated Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 96. GSK Varicella Attenuated Live Vaccine Product
Table 97. GSK Recent Development
Table 98. Keygen Company Information
Table 99. Keygen Description and Business Overview
Table 100. Keygen Varicella Attenuated Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 101. Keygen Varicella Attenuated Live Vaccine Product
Table 102. Keygen Recent Development
Table 103. Green Cross Company Information
Table 104. Green Cross Description and Business Overview
Table 105. Green Cross Varicella Attenuated Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 106. Green Cross Varicella Attenuated Live Vaccine Product
Table 107. Green Cross Recent Development
Table 108. Biken Company Information
Table 109. Biken Description and Business Overview
Table 110. Biken Varicella Attenuated Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 111. Biken Varicella Attenuated Live Vaccine Product
Table 112. Biken Recent Development
Table 113. Shanghai Rongsheng Biotech Company Information
Table 114. Shanghai Rongsheng Biotech Description and Business Overview
Table 115. Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 116. Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccine Product
Table 117. Shanghai Rongsheng Biotech Recent Development
Table 118. Changchun Changsheng Life Sciences Limited Company Information
Table 119. Changchun Changsheng Life Sciences Limited Description and Business Overview
Table 120. Changchun Changsheng Life Sciences Limited Varicella Attenuated Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 121. Changchun Changsheng Life Sciences Limited Varicella Attenuated Live Vaccine Product
Table 122. Changchun Changsheng Life Sciences Limited Recent Development
Table 123. Production Base and Market Concentration Rate of Raw Material
Table 124. Key Suppliers of Raw Materials
Table 125. Varicella Attenuated Live Vaccine Distributors List
Table 126. Varicella Attenuated Live Vaccine Customers List
Table 127. Varicella Attenuated Live Vaccine Market Trends
Table 128. Varicella Attenuated Live Vaccine Market Drivers
Table 129. Varicella Attenuated Live Vaccine Market Challenges
Table 130. Varicella Attenuated Live Vaccine Market Restraints
Table 131. Research Programs/Design for This Report
Table 132. Key Data Information from Secondary Sources
Table 133. Key Data Information from Primary Sources
List of Figures
Figure 1. Varicella Attenuated Live Vaccine Product Picture
Figure 2. Global Varicella Attenuated Live Vaccine Sales (US$ Million) by Type (2020 & 2024 & 2031)
Figure 3. Global Varicella Attenuated Live Vaccine Sales Market Share by Type in 2024 & 2031
Figure 4. Monovalent Vaccine Product Picture
Figure 5. Combination Vaccine Product Picture
Figure 6. Global Varicella Attenuated Live Vaccine Sales (US$ Million) by Application (2020 & 2024 & 2031)
Figure 7. Global Varicella Attenuated Live Vaccine Sales Market Share by Application in 2024 & 2031
Figure 8. Kids Injection Examples
Figure 9. Adults Injection Examples
Figure 10. Global Varicella Attenuated Live Vaccine Sales, (US$ Million), 2020 VS 2024 VS 2031
Figure 11. Global Varicella Attenuated Live Vaccine Sales Growth Rate (2020-2031) & (US$ Million)
Figure 12. Global Varicella Attenuated Live Vaccine Sales (K Doses) Growth Rate (2020-2031)
Figure 13. Global Varicella Attenuated Live Vaccine Price Trends Growth Rate (2020-2031) & (USD/Dose)
Figure 14. Varicella Attenuated Live Vaccine Report Years Considered
Figure 15. Global Market Varicella Attenuated Live Vaccine Market Size (US$ Million) by Region:2020 VS 2024 VS 2031
Figure 16. Global Varicella Attenuated Live Vaccine Revenue Market Share by Region: 2020 VS 2024
Figure 17. North America Varicella Attenuated Live Vaccine Revenue (US$ Million) Growth Rate (2020-2031)
Figure 18. North America Varicella Attenuated Live Vaccine Sales (K Doses) Growth Rate (2020-2031)
Figure 19. Europe Varicella Attenuated Live Vaccine Revenue (US$ Million) Growth Rate (2020-2031)
Figure 20. Europe Varicella Attenuated Live Vaccine Sales (K Doses) Growth Rate (2020-2031)
Figure 21. China Varicella Attenuated Live Vaccine Revenue (US$ Million) Growth Rate (2020-2031)
Figure 22. China Varicella Attenuated Live Vaccine Sales (K Doses) Growth Rate (2020-2031)
Figure 23. Japan Varicella Attenuated Live Vaccine Revenue (US$ Million) Growth Rate (2020-2031)
Figure 24. Japan Varicella Attenuated Live Vaccine Sales (K Doses) Growth Rate (2020-2031)
Figure 25. South Korea Varicella Attenuated Live Vaccine Revenue (US$ Million) Growth Rate (2020-2031)
Figure 26. South Korea Varicella Attenuated Live Vaccine Sales (K Doses) Growth Rate (2020-2031)
Figure 27. Global Varicella Attenuated Live Vaccine Revenue Share by Type (2020-2025)
Figure 28. Global Varicella Attenuated Live Vaccine Sales Share by Type (2026-2031)
Figure 29. Global Varicella Attenuated Live Vaccine Revenue Share by Type (2026-2031)
Figure 30. Global Varicella Attenuated Live Vaccine Revenue Share by Application (2020-2025)
Figure 31. Global Varicella Attenuated Live Vaccine Revenue Growth Rate by Application in 2020 & 2024
Figure 32. Global Varicella Attenuated Live Vaccine Sales Share by Application (2026-2031)
Figure 33. Global Varicella Attenuated Live Vaccine Revenue Share by Application (2026-2031)
Figure 34. Global Varicella Attenuated Live Vaccine Sales Share by Company (2024)
Figure 35. Global Varicella Attenuated Live Vaccine Revenue Share by Company (2024)
Figure 36. Global 5 Largest Varicella Attenuated Live Vaccine Players Market Share by Revenue in Varicella Attenuated Live Vaccine: 2020 & 2024
Figure 37. Varicella Attenuated Live Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 38. Manufacturing Cost Structure of Varicella Attenuated Live Vaccine
Figure 39. Manufacturing Process Analysis of Varicella Attenuated Live Vaccine
Figure 40. Varicella Attenuated Live Vaccine Industrial Chain
Figure 41. Channels of Distribution (Direct Vs Distribution)
Figure 42. Distributors Profiles
Figure 43. Bottom-up and Top-down Approaches for This Report
Figure 44. Data Triangulation
Figure 45. Key Executives Interviewed
Table 1. Global Varicella Attenuated Live Vaccine Sales (US$ Million) Growth Rate by Type (2020 & 2024 & 2031)
Table 2. Global Varicella Attenuated Live Vaccine Sales (US$ Million) Comparison by Application (2020 & 2024 & 2031)
Table 3. Global Market Varicella Attenuated Live Vaccine Market Size (US$ Million) by Region:2020 VS 2024 VS 2031
Table 4. Global Varicella Attenuated Live Vaccine Sales (K Doses) by Region (2020-2025)
Table 5. Global Varicella Attenuated Live Vaccine Sales Market Share by Region (2020-2025)
Table 6. Global Varicella Attenuated Live Vaccine Revenue (US$ Million) Market Share by Region (2020-2025)
Table 7. Global Varicella Attenuated Live Vaccine Revenue Share by Region (2020-2025)
Table 8. Global Varicella Attenuated Live Vaccine Sales (K Doses) Forecast by Region (2026-2031)
Table 9. Global Varicella Attenuated Live Vaccine Sales Market Share Forecast by Region (2026-2031)
Table 10. Global Varicella Attenuated Live Vaccine Revenue (US$ Million) Forecast by Region (2026-2031)
Table 11. Global Varicella Attenuated Live Vaccine Revenue Share Forecast by Region (2026-2031)
Table 12. Global Varicella Attenuated Live Vaccine Sales by Type (K Doses) & (2020-2025)
Table 13. Global Varicella Attenuated Live Vaccine Sales Share by Type (2020-2025)
Table 14. Global Varicella Attenuated Live Vaccine Revenue by Type (US$ Million) & (2020-2025)
Table 15. Global Varicella Attenuated Live Vaccine Price by Type (USD/Dose) & (2020-2025)
Table 16. Global Varicella Attenuated Live Vaccine Sales by Type (K Doses) & (2026-2031)
Table 17. Global Varicella Attenuated Live Vaccine Revenue by Type (US$ Million) & (2026-2031)
Table 18. Global Varicella Attenuated Live Vaccine Price by Type (USD/Dose) & (2026-2031)
Table 19. Representative Players of Each Type
Table 20. Global Varicella Attenuated Live Vaccine Sales by Application (K Doses) & (2020-2025)
Table 21. Global Varicella Attenuated Live Vaccine Sales Share by Application (2020-2025)
Table 22. Global Varicella Attenuated Live Vaccine Revenue by Application (US$ Million) & (2020-2025)
Table 23. Global Varicella Attenuated Live Vaccine Price by Application (USD/Dose) & (2020-2025)
Table 24. Global Varicella Attenuated Live Vaccine Sales by Application (K Doses) & (2026-2031)
Table 25. Global Varicella Attenuated Live Vaccine Revenue Market Share by Application (US$ Million) & (2026-2031)
Table 26. Global Varicella Attenuated Live Vaccine Price by Application (USD/Dose) & (2026-2031)
Table 27. New Sources of Growth in Varicella Attenuated Live Vaccine Application
Table 28. Global Varicella Attenuated Live Vaccine Sales by Company (K Doses) & (2020-2025)
Table 29. Global Varicella Attenuated Live Vaccine Sales Share by Company (2020-2025)
Table 30. Global Varicella Attenuated Live Vaccine Revenue by Company (US$ Million) & (2020-2025)
Table 31. Global Varicella Attenuated Live Vaccine Revenue Share by Company (2020-2025)
Table 32. Global Varicella Attenuated Live Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Varicella Attenuated Live Vaccine as of 2024)
Table 33. Global Market Varicella Attenuated Live Vaccine Average Price by Company (USD/Dose) & (2020-2025)
Table 34. Global Key Manufacturers of Varicella Attenuated Live Vaccine, Manufacturing Sites & Headquarters
Table 35. Global Key Manufacturers of Varicella Attenuated Live Vaccine, Product Type & Application
Table 36. Global Key Manufacturers of Varicella Attenuated Live Vaccine, Date of Enter into This Industry
Table 37. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 38. North America Varicella Attenuated Live Vaccine Sales by Company (2020-2025) & (K Doses)
Table 39. North America Varicella Attenuated Live Vaccine Sales Market Share by Company (2020-2025)
Table 40. North America Varicella Attenuated Live Vaccine Revenue by Company (2020-2025) & (US$ Million)
Table 41. North America Varicella Attenuated Live Vaccine Revenue Market Share by Company (2020-2025)
Table 42. North America Varicella Attenuated Live Vaccine Sales by Type (2020-2025) & (K Doses)
Table 43. North America Varicella Attenuated Live Vaccine Sales Market Share by Type (2020-2025)
Table 44. North America Varicella Attenuated Live Vaccine Sales by Application (2020-2025) & (K Doses)
Table 45. North America Varicella Attenuated Live Vaccine Sales Market Share by Application (2020-2025)
Table 46. Europe Varicella Attenuated Live Vaccine Sales by Company (2020-2025) & (K Doses)
Table 47. Europe Varicella Attenuated Live Vaccine Sales Market Share by Company (2020-2025)
Table 48. Europe Varicella Attenuated Live Vaccine Revenue by Company (2020-2025) & (US$ Million)
Table 49. Europe Varicella Attenuated Live Vaccine Revenue Market Share by Company (2020-2025)
Table 50. Europe Varicella Attenuated Live Vaccine Sales by Type (2020-2025) & (K Doses)
Table 51. Europe Varicella Attenuated Live Vaccine Sales Market Share by Type (2020-2025)
Table 52. Europe Varicella Attenuated Live Vaccine Sales by Application (2020-2025) & (K Doses)
Table 53. Europe Varicella Attenuated Live Vaccine Sales Market Share by Application (2020-2025)
Table 54. China Varicella Attenuated Live Vaccine Sales by Company (2020-2025) & (K Doses)
Table 55. China Varicella Attenuated Live Vaccine Sales Market Share by Company (2020-2025)
Table 56. China Varicella Attenuated Live Vaccine Revenue by Company (2020-2025) & (US$ Million)
Table 57. China Varicella Attenuated Live Vaccine Revenue Market Share by Company (2020-2025)
Table 58. China Varicella Attenuated Live Vaccine Sales by Type (2020-2025) & (K Doses)
Table 59. China Varicella Attenuated Live Vaccine Sales Market Share by Type (2020-2025)
Table 60. China Varicella Attenuated Live Vaccine Sales by Application (2020-2025) & (K Doses)
Table 61. China Varicella Attenuated Live Vaccine Sales Market Share by Application (2020-2025)
Table 62. Japan Varicella Attenuated Live Vaccine Sales by Company (2020-2025) & (K Doses)
Table 63. Japan Varicella Attenuated Live Vaccine Sales Market Share by Company (2020-2025)
Table 64. Japan Varicella Attenuated Live Vaccine Revenue by Company (2020-2025) & (US$ Million)
Table 65. Japan Varicella Attenuated Live Vaccine Revenue Market Share by Company (2020-2025)
Table 66. Japan Varicella Attenuated Live Vaccine Sales by Type (2020-2025) & (K Doses)
Table 67. Japan Varicella Attenuated Live Vaccine Sales Market Share by Type (2020-2025)
Table 68. Japan Varicella Attenuated Live Vaccine Sales by Application (2020-2025) & (K Doses)
Table 69. Japan Varicella Attenuated Live Vaccine Sales Market Share by Application (2020-2025)
Table 70. South Korea Varicella Attenuated Live Vaccine Sales by Company (2020-2025) & (K Doses)
Table 71. South Korea Varicella Attenuated Live Vaccine Sales Market Share by Company (2020-2025)
Table 72. South Korea Varicella Attenuated Live Vaccine Revenue by Company (2020-2025) & (US$ Million)
Table 73. South Korea Varicella Attenuated Live Vaccine Revenue Market Share by Company (2020-2025)
Table 74. South Korea Varicella Attenuated Live Vaccine Sales by Type (2020-2025) & (K Doses)
Table 75. South Korea Varicella Attenuated Live Vaccine Sales Market Share by Type (2020-2025)
Table 76. South Korea Varicella Attenuated Live Vaccine Sales by Application (2020-2025) & (K Doses)
Table 77. South Korea Varicella Attenuated Live Vaccine Sales Market Share by Application (2020-2025)
Table 78. Merck Company Information
Table 79. Merck Description and Business Overview
Table 80. Merck Varicella Attenuated Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 81. Merck Varicella Attenuated Live Vaccine Product
Table 82. Merck Recent Development
Table 83. BCHT Company Information
Table 84. BCHT Description and Business Overview
Table 85. BCHT Varicella Attenuated Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 86. BCHT Varicella Attenuated Live Vaccine Product
Table 87. BCHT Recent Development
Table 88. Shanghai Institute Company Information
Table 89. Shanghai Institute Description and Business Overview
Table 90. Shanghai Institute Varicella Attenuated Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 91. Shanghai Institute Varicella Attenuated Live Vaccine Product
Table 92. Shanghai Institute Recent Development
Table 93. GSK Company Information
Table 94. GSK Description and Business Overview
Table 95. GSK Varicella Attenuated Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 96. GSK Varicella Attenuated Live Vaccine Product
Table 97. GSK Recent Development
Table 98. Keygen Company Information
Table 99. Keygen Description and Business Overview
Table 100. Keygen Varicella Attenuated Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 101. Keygen Varicella Attenuated Live Vaccine Product
Table 102. Keygen Recent Development
Table 103. Green Cross Company Information
Table 104. Green Cross Description and Business Overview
Table 105. Green Cross Varicella Attenuated Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 106. Green Cross Varicella Attenuated Live Vaccine Product
Table 107. Green Cross Recent Development
Table 108. Biken Company Information
Table 109. Biken Description and Business Overview
Table 110. Biken Varicella Attenuated Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 111. Biken Varicella Attenuated Live Vaccine Product
Table 112. Biken Recent Development
Table 113. Shanghai Rongsheng Biotech Company Information
Table 114. Shanghai Rongsheng Biotech Description and Business Overview
Table 115. Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 116. Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccine Product
Table 117. Shanghai Rongsheng Biotech Recent Development
Table 118. Changchun Changsheng Life Sciences Limited Company Information
Table 119. Changchun Changsheng Life Sciences Limited Description and Business Overview
Table 120. Changchun Changsheng Life Sciences Limited Varicella Attenuated Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 121. Changchun Changsheng Life Sciences Limited Varicella Attenuated Live Vaccine Product
Table 122. Changchun Changsheng Life Sciences Limited Recent Development
Table 123. Production Base and Market Concentration Rate of Raw Material
Table 124. Key Suppliers of Raw Materials
Table 125. Varicella Attenuated Live Vaccine Distributors List
Table 126. Varicella Attenuated Live Vaccine Customers List
Table 127. Varicella Attenuated Live Vaccine Market Trends
Table 128. Varicella Attenuated Live Vaccine Market Drivers
Table 129. Varicella Attenuated Live Vaccine Market Challenges
Table 130. Varicella Attenuated Live Vaccine Market Restraints
Table 131. Research Programs/Design for This Report
Table 132. Key Data Information from Secondary Sources
Table 133. Key Data Information from Primary Sources
List of Figures
Figure 1. Varicella Attenuated Live Vaccine Product Picture
Figure 2. Global Varicella Attenuated Live Vaccine Sales (US$ Million) by Type (2020 & 2024 & 2031)
Figure 3. Global Varicella Attenuated Live Vaccine Sales Market Share by Type in 2024 & 2031
Figure 4. Monovalent Vaccine Product Picture
Figure 5. Combination Vaccine Product Picture
Figure 6. Global Varicella Attenuated Live Vaccine Sales (US$ Million) by Application (2020 & 2024 & 2031)
Figure 7. Global Varicella Attenuated Live Vaccine Sales Market Share by Application in 2024 & 2031
Figure 8. Kids Injection Examples
Figure 9. Adults Injection Examples
Figure 10. Global Varicella Attenuated Live Vaccine Sales, (US$ Million), 2020 VS 2024 VS 2031
Figure 11. Global Varicella Attenuated Live Vaccine Sales Growth Rate (2020-2031) & (US$ Million)
Figure 12. Global Varicella Attenuated Live Vaccine Sales (K Doses) Growth Rate (2020-2031)
Figure 13. Global Varicella Attenuated Live Vaccine Price Trends Growth Rate (2020-2031) & (USD/Dose)
Figure 14. Varicella Attenuated Live Vaccine Report Years Considered
Figure 15. Global Market Varicella Attenuated Live Vaccine Market Size (US$ Million) by Region:2020 VS 2024 VS 2031
Figure 16. Global Varicella Attenuated Live Vaccine Revenue Market Share by Region: 2020 VS 2024
Figure 17. North America Varicella Attenuated Live Vaccine Revenue (US$ Million) Growth Rate (2020-2031)
Figure 18. North America Varicella Attenuated Live Vaccine Sales (K Doses) Growth Rate (2020-2031)
Figure 19. Europe Varicella Attenuated Live Vaccine Revenue (US$ Million) Growth Rate (2020-2031)
Figure 20. Europe Varicella Attenuated Live Vaccine Sales (K Doses) Growth Rate (2020-2031)
Figure 21. China Varicella Attenuated Live Vaccine Revenue (US$ Million) Growth Rate (2020-2031)
Figure 22. China Varicella Attenuated Live Vaccine Sales (K Doses) Growth Rate (2020-2031)
Figure 23. Japan Varicella Attenuated Live Vaccine Revenue (US$ Million) Growth Rate (2020-2031)
Figure 24. Japan Varicella Attenuated Live Vaccine Sales (K Doses) Growth Rate (2020-2031)
Figure 25. South Korea Varicella Attenuated Live Vaccine Revenue (US$ Million) Growth Rate (2020-2031)
Figure 26. South Korea Varicella Attenuated Live Vaccine Sales (K Doses) Growth Rate (2020-2031)
Figure 27. Global Varicella Attenuated Live Vaccine Revenue Share by Type (2020-2025)
Figure 28. Global Varicella Attenuated Live Vaccine Sales Share by Type (2026-2031)
Figure 29. Global Varicella Attenuated Live Vaccine Revenue Share by Type (2026-2031)
Figure 30. Global Varicella Attenuated Live Vaccine Revenue Share by Application (2020-2025)
Figure 31. Global Varicella Attenuated Live Vaccine Revenue Growth Rate by Application in 2020 & 2024
Figure 32. Global Varicella Attenuated Live Vaccine Sales Share by Application (2026-2031)
Figure 33. Global Varicella Attenuated Live Vaccine Revenue Share by Application (2026-2031)
Figure 34. Global Varicella Attenuated Live Vaccine Sales Share by Company (2024)
Figure 35. Global Varicella Attenuated Live Vaccine Revenue Share by Company (2024)
Figure 36. Global 5 Largest Varicella Attenuated Live Vaccine Players Market Share by Revenue in Varicella Attenuated Live Vaccine: 2020 & 2024
Figure 37. Varicella Attenuated Live Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 38. Manufacturing Cost Structure of Varicella Attenuated Live Vaccine
Figure 39. Manufacturing Process Analysis of Varicella Attenuated Live Vaccine
Figure 40. Varicella Attenuated Live Vaccine Industrial Chain
Figure 41. Channels of Distribution (Direct Vs Distribution)
Figure 42. Distributors Profiles
Figure 43. Bottom-up and Top-down Approaches for This Report
Figure 44. Data Triangulation
Figure 45. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Smart Grid Digital Substation Market Research Report 2026
Mar 17, 26
Global Photovoltaic Molded Case Circuit Breaker Market Research Report 2026
Mar 17, 26
Global Roll-Roll Automobile Business Market Research Report 2026
Mar 17, 26
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232